Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Free Cash Flow (2017 - 2025)

Historic Free Cash Flow for Crinetics Pharmaceuticals (CRNX) over the last 9 years, with Q3 2025 value amounting to -$111.6 million.

  • Crinetics Pharmaceuticals' Free Cash Flow fell 7613.14% to -$111.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$354.0 million, marking a year-over-year decrease of 7218.95%. This contributed to the annual value of -$229.8 million for FY2024, which is 3439.81% down from last year.
  • Per Crinetics Pharmaceuticals' latest filing, its Free Cash Flow stood at -$111.6 million for Q3 2025, which was down 7613.14% from -$89.1 million recorded in Q2 2025.
  • Over the past 5 years, Crinetics Pharmaceuticals' Free Cash Flow peaked at -$13.6 million during Q1 2022, and registered a low of -$111.6 million during Q3 2025.
  • For the 5-year period, Crinetics Pharmaceuticals' Free Cash Flow averaged around -$47.2 million, with its median value being -$40.8 million (2023).
  • As far as peak fluctuations go, Crinetics Pharmaceuticals' Free Cash Flow skyrocketed by 3246.79% in 2022, and later tumbled by 19898.02% in 2023.
  • Quarter analysis of 5 years shows Crinetics Pharmaceuticals' Free Cash Flow stood at -$22.9 million in 2021, then crashed by 54.82% to -$35.5 million in 2022, then fell by 11.19% to -$39.4 million in 2023, then tumbled by 61.41% to -$63.7 million in 2024, then tumbled by 75.23% to -$111.6 million in 2025.
  • Its Free Cash Flow stands at -$111.6 million for Q3 2025, versus -$89.1 million for Q2 2025 and -$89.7 million for Q1 2025.